Paper42979080PubMed
Pathological progression features-guided biphasic drug delivery supramolecular hydrogel for synergistic cartilage protection in osteoarthritis.
Lin J and 6 others. Acta Pharm Sin B, 2026.
Cite this record
ConductScience Library. Pathological progression features-guided biphasic drug delivery supramolecular hydrogel for synergistic cartilage protection in osteoarthritis. Papers, record 42979080. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979080
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Pathological progression features-guided biphasic drug delivery supramolecular hydrogel for synergistic cartilage protection in osteoarthritis.
- Journal
- Acta Pharm Sin B
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37593145 | Dual-engineered cartilage-targeting extracellular vesicles derived from mesenchymal stem cells enhance osteoarthritis treatment via miR-223/NLRP3/pyroptosis axis: Toward a precision therapy. | Bioact Mater | 2023 | https://conductscience.org/library/papers/37593145 | PubMed |
| 2 | 35526013 | Multifunctional thermo-sensitive hydrogel for modulating the microenvironment in Osteoarthritis by polarizing macrophages and scavenging RONS. | J Nanobiotechnology | 2022 | https://conductscience.org/library/papers/35526013 | PubMed |
| 3 | 39948092 | Osteoarthritis. | Nat Rev Dis Primers | 2025 | https://conductscience.org/library/papers/39948092 | PubMed |
| 4 | 33116121 | Macrophage-derived extracellular vesicles: diverse mediators of pathology and therapeutics in multiple diseases. | Cell Death Dis | 2020 | https://conductscience.org/library/papers/33116121 | PubMed |
| 5 | 33014529 | Pyroptosis Plays a Role in Osteoarthritis. | Aging Dis | 2020 | https://conductscience.org/library/papers/33014529 | PubMed |
| 6 | 32616761 | Synovial cell cross-talk with cartilage plays a major role in the pathogenesis of osteoarthritis. | Sci Rep | 2020 | https://conductscience.org/library/papers/32616761 | PubMed |
| 7 | 25969431 | Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. | Ann Rheum Dis | 2015 | https://conductscience.org/library/papers/25969431 | PubMed |
| 8 | 32367036 | FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. | Nat Immunol | 2020 | https://conductscience.org/library/papers/32367036 | PubMed |
| 9 | 35353555 | Stem cell-homing hydrogel-based miR-29b-5p delivery promotes cartilage regeneration by suppressing senescence in an osteoarthritis rat model. | Sci Adv | 2022 | https://conductscience.org/library/papers/35353555 | PubMed |
| 10 | 37422640 | Targeting macrophagic PIM-1 alleviates osteoarthritis by inhibiting NLRP3 inflammasome activation via suppressing mitochondrial ROS/Cl- efflux signaling pathway. | J Transl Med | 2023 | https://conductscience.org/library/papers/37422640 | PubMed |
| 11 | 35093823 | Injectable hydrogels with high drug loading through B-N coordination and ROS-triggered drug release for efficient treatment of chronic periodontitis in diabetic rats. | Biomaterials | 2022 | https://conductscience.org/library/papers/35093823 | PubMed |
| 12 | 40078882 | Up IGF-I via high-toughness adaptive hydrogels for remodeling growth plate of children. | Regen Biomater | 2025 | https://conductscience.org/library/papers/40078882 | PubMed |
| 13 | 38173842 | Lysosomal destabilization: A missing link between pathological calcification and osteoarthritis. | Bioact Mater | 2024 | https://conductscience.org/library/papers/38173842 | PubMed |
| 14 | 34921569 | A Logic-Based Diagnostic and Therapeutic Hydrogel with Multistimuli Responsiveness to Orchestrate Diabetic Bone Regeneration. | Adv Mater | 2022 | https://conductscience.org/library/papers/34921569 | PubMed |
| 15 | 34466714 | Injectable polymeric nanoparticle hydrogel system for long-term anti-inflammatory effect to treat osteoarthritis. | Bioact Mater | 2022 | https://conductscience.org/library/papers/34466714 | PubMed |
| 16 | 41311383 | A thermo-sensitive hydrogel targeting macrophage reprogramming for sustained osteoarthritis pain relief. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/41311383 | PubMed |
| 17 | 37078123 | A cyclic brush zwitterionic polymer based pH-responsive nanocarrier-mediated dual drug delivery system with lubrication maintenance for osteoarthritis treatment. | Mater Horiz | 2023 | https://conductscience.org/library/papers/37078123 | PubMed |
| 18 | 35415286 | Shear-responsive boundary-lubricated hydrogels attenuate osteoarthritis. | Bioact Mater | 2022 | https://conductscience.org/library/papers/35415286 | PubMed |
| 19 | 36053817 | ALPK1 Accelerates the Pathogenesis of Osteoarthritis by Activating NLRP3 Signaling. | J Bone Miner Res | 2022 | https://conductscience.org/library/papers/36053817 | PubMed |
| 20 | 14759124 | Applications of the ninhydrin reaction for analysis of amino acids, peptides, and proteins to agricultural and biomedical sciences. | J Agric Food Chem | 2004 | https://conductscience.org/library/papers/14759124 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42979080
GET https://conductscience.org/api/papers/v1/42979080/references?page=2